AI
MRSN

Atom Investors’s Mersana Therapeutics MRSN Stock Holding History

Atom Investors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,063
Closed -$38K – 593
2024
Q4 		$38K Buy
1,063
+77
+8% +$3.98K ﹤0.01% 475
2024
Q3 		$46.6K Sell
986
-13,631
-93% -$601K ﹤0.01% 450
2024
Q2 		$735K Sell
14,617
-2,952
-17% -$213K 0.07% 286
2024
Q1 		$1.97M Sell
17,569
-13,417
-43% -$1.33M 0.25% 134
2023
Q4 		$1.8M Buy
30,986
+19,259
+164% +$775K 0.32% 107
2023
Q3 		$372K Buy
+11,727
New +$557K 0.08% 280
2022
Q4 		– Sell
-1,004
Closed -$170K – 283
2022
Q3 		$170K Buy
+1,004
New +$163K 0.06% 222
2021
Q1 		– Sell
-15,165
Closed -$10.1M – 365
2020
Q4 		$10.1M Buy
15,165
+941
+7% +$523K 1.02% 25
2020
Q3 		$6.62M Buy
14,224
+11,538
+430% +$5.83M 0.63% 32
2020
Q2 		$1.57M Buy
+2,686
New +$917K 0.1% 165

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Atom Investors's MRSN Position: Q1 2025 in Review

Atom Investors sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 1,063 shares — an estimated $38K sold.

Atom Investors first reported a position in MRSN in Q2 2020 and held it in 10 quarters. The position peaked at $10.1M in Q4 2020. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Atom Investors reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Atom Investors sold 1,063 Mersana Therapeutics shares in Q1 2025, an estimated $38K.
  • Atom Investors first reported a position in Mersana Therapeutics in Q2 2020 and held it in 10 quarters.
  • Atom Investors's Mersana Therapeutics position peaked at $10.1M in Q4 2020.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Atom Investors's 13F filing for Q1 2025, filed 15 May 2025.